Key Biomarkers in the RGCC Onconomics Plus Report: What They Mean
Onconomics Plus is an advanced personalized oncology assessment developed by RGCC.
In addition to testing the sensitivity of circulating tumor cells to various natural substances and pharmaceutical agents,
it also includes a range of key biomarkers closely associated with tumor behavior.
These biomarkers provide vital insights for designing personalized support strategies, risk evaluation, and ongoing monitoring.
What Are Biomarkers?
Biomarkers are molecular indicators that reflect the biological behavior, aggressiveness, and signaling patterns of cancer cells.
By analyzing these markers, we can better understand:
- Whether a tumor is likely to be aggressive or prone to metastasis
- Whether specific growth or inflammation-related pathways are activated
- Which natural compounds may help modulate these mechanisms
- Whether a person might benefit from complementary or non-pharmaceutical support options
Interpretation of Common Key Biomarkers
1.VEGF
(Vascular Endothelial Growth Factor)
- Indicates the tumor’s ability to promote new blood vessel growth, which supports rapid expansion and potential metastasis.
- Natural anti-angiogenic support may include compounds like EGCG (green tea extract) and curcumin.
2.EGFR
(Epidermal Growth Factor Receptor)
- Linked to cell proliferation and tumor progression when overactivated.
- May be balanced using natural compounds such as ganoderic acid (from reishi) or quercetin.
3.MMP-2 / MMP-9
(Matrix Metalloproteinases)
- These enzymes enable cancer cells to break down surrounding tissues, facilitating invasion and spread.
- Elevated levels suggest a need for antioxidant and anti-inflammatory nutritional support.
4.HER2 / neu
(Human Epidermal Growth Factor Receptor 2)
- Overexpression is associated with uncontrolled cell division, especially in breast and gastric cancers.
- Positive expression should be professionally evaluated to consider additional complementary support strategies.
5.IL-6
(Interleukin-6)
- A major marker of chronic inflammation and immune imbalance. Elevated levels can worsen the tumor microenvironment.
- Managing stress, improving diet, and anti-inflammatory support are crucial.
6.PD-L1
(Programmed Death-Ligand 1)
- Associated with immune evasion. This marker helps assess whether immune-supportive strategies may be beneficial.
- High expression may align with the use of immune-modulating agents like beta-glucans.
7.C-kit
(Stem Cell Factor Receptor)
- Related to the self-renewal capacity and persistence of cancer stem cells.
- When overexpressed, long-term planning and multi-targeted approaches may be needed.
Conclusion: Every Marker Is a Guidepost
Biomarkers are more than numbers—they are signals from the body.
By interpreting the RGCC Onconomics Plus report, we gain a clearer picture of an individual’s biological landscape.
These insights provide a solid foundation for tailoring nutrition, lifestyle modifications, and professional support strategies.
In the journey toward personalized integrative wellness,
these biomarkers are not just indicators of risk—they are starting points for informed and empowered action.
Medical Disclaimer:
The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.